NLM Digital Collections

Search

Start Over Formats Text ✖Remove constraint Formats: Text Subjects Opiate Substitution Treatment ✖Remove constraint Subjects: Opiate Substitution Treatment Copyright Public domain ✖Remove constraint Copyright: Public domain

1. Opioid use disorders: HHS needs measures to assess the effectiveness of efforts to expand access to medication-assisted treatment : report to majority leader, U.S. Senate

Publication:
Washington, DC : United States Government Accountability Office, October 2017
Subject(s):
Health Services Accessibility
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Outcome Assessment (Health Care)
Community-Institutional Relations
Buprenorphine -- therapeutic use
Inservice Training
Insurance Coverage
Methadone -- therapeutic use
Naloxone -- therapeutic use
Naltrexone -- therapeutic use
Prescription Drug Diversion -- prevention & control
Humans
United States
United States. Department of Health and Human Services.

2. Flexibilities in controlled substances prescribing and dispensing during the COVID-19 pandemic

Publication:
Washington, D.C. : Assistant Secretary for Planning and Evaluation, Office of Science & Data Policy, August 2022
Subject(s):
Controlled Substances -- supply & distribution
COVID-19
Electronic Prescribing
Federal Government
Health Services Accessibility
Opiate Substitution Treatment
State Government
United States

3. Opioid use disorder: barriers to Medicaid beneficiaries' access to treatment medications : report to Congressional committees

Publication:
Washington, DC : United States Government Accountability Office, January 2020
Subject(s):
Analgesics, Opioid -- supply & distribution
Analgesics, Opioid -- therapeutic use
Health Services Accessibility
Medicaid -- economics
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
United States
Centers for Medicare & Medicaid Services (U.S.)

4. Geographic disparities affect access to buprenorphine services for opioid use disorder

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, January 2020
Subject(s):
Buprenorphine -- supply & distribution
Health Services Accessibility
Medically Underserved Area
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
United States
United States. Department of Health and Human Services
United States. Substance Abuse and Mental Health Services Administration

6. Opioid use disorder: developing depot buprenorphine products for treatment

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, February 2019
Subject(s):
Buprenorphine -- therapeutic use
Drug Development
Opioid-Related Disorders -- drug therapy
Buprenorphine -- administration & dosage
Clinical Trials as Topic
Delayed-Action Preparations
Narcotic Antagonists
Opiate Substitution Treatment
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

7. Opioid use decreased in Medicare Part D, while medication-assisted treatment increased

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, July 2019
Subject(s):
Analgesics, Opioid -- therapeutic use
Medicare Part D
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Drug Overdose -- drug therapy
Drug Utilization -- trends
Forecasting
Inappropriate Prescribing
Naloxone -- therapeutic use
State Government
Humans
United States

8. Many Medicaid enrollees with opioid use disorder were treated with medication: however, disparities present concerns

Publication:
Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2023
Subject(s):
Ethnic and Racial Minorities -- statistics & numerical data
Government Regulation
Health Inequities
Healthcare Disparities
Medicaid
Morphinans -- supply & distribution
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
United States

9. The risk of misuse and diversion of buprenorphine for opioid use disorder in Medicare Part D continues to appear low: 2022

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2023
Subject(s):
Buprenorphine
Drug Users -- statistics & numerical data
Government Regulation
Medicare Part D -- economics
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Prescription Drug Diversion -- statistics & numerical data
United States